MoonLake Immunotherapeutics
MLTXHealthcareNASDAQBiotechnology · Last scanned Sep 7, 2026
Scan Results
Daily timeframePart of the healthcare sector, MoonLake Immunotherapeutics (MLTX) is listed under Biotechnology. The $1.28B market capitalization puts MLTX squarely in small-cap range for its industry. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
Market Cap
$1.28B
Beta
1.03
P/E (TTM)
—
P/E (Fwd)
-4.51
EPS (TTM)
$-3.84
EPS (Fwd)
$-3.33
ROE
-67.5%
ROA
-32.4%
Cash
$537.0M
Total Debt
$101.5M
Free CF
-$131.9M
52W Change
-73.7%
Annual Financials
Cash vs Debt
Where MLTX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, MLTX finished 15.06% below its 150-day moving average ($17.73) and 10.78% below its 200-day moving average ($16.88). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MLTX overbought or oversold?
At the September 3, 2026 close, MLTX's RSI(14) was 26.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
MoonLake Immunotherapeutics holds $537.0M in cash against $101.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$131.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -67.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence MoonLake Immunotherapeutics's trajectory.